Apple's stock surged over 6% on Tuesday following the announcement of its new AI platform, Apple Intelligence.
D.A. Davidson upgraded Apple to Buy and raised its price target to $230 after the event.
Microsoft and Google have offered free or discounted cybersecurity services to rural hospitals in the US.
The platform, which is expected to be available for iPhone 15 Pro, iPads, Macs running M1 series chips and newer later this fall, includes updates to Siri that can parse phone addresses from messages or find photos based on voice prompts.
Apple's Stock Surges to Record High Amid Excitement for New AI Platform, Apple Intelligence
Tech giant Apple saw its stock reach an intraday record of over 6% surge on Tuesday as investors digested the announcement of its new artificial intelligence (AI) platform, Apple Intelligence. The platform was unveiled at the company's annual Worldwide Developers Conference (WWDC) on Monday and is expected to be available for iPhone 15 Pro, iPads, Macs running M1 series chips and newer later this fall.
Key features of the launch include updates to Siri that can parse phone addresses from messages or find photos based on voice prompts. D.A. Davidson managing director Gil Luria upgraded Apple to Buy from Neutral and raised his price target to $230 after Monday's event, stating that the new AI capabilities will integrate into everyday life.
The tech sector was mixed on Tuesday as the Dow had a bad day while the S&P 500 and Nasdaq Composite moved higher. The Federal Reserve is expected to announce its interest-rate decision in the afternoon on Wednesday, with no one expecting a move now but investors hoping for cuts later this year if price gains are under control.
Microsoft and Google have also made headlines by offering free or discounted cybersecurity services to rural hospitals in the US to protect them against cyberattacks that have disrupted patient care and threatened lives. The economic news comes as persistent inflation continues to impact the US economy, despite strong job growth.
Madrigal Pharmaceuticals' liver disease therapy Rezdiffra is predicted to be the 'Biggest 2024 Launch in Biotech'' according to Wolfe Research analyst Andy Chen.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
The article contains an appeal to authority fallacy when Wolfe Research is quoted as calling Madrigal Pharmaceuticals' drug the 'Biggest 2024 Launch in Biotech.' This statement is not a logical conclusion and is based on the opinion of one analyst. Additionally, there are some instances of inflammatory rhetoric, such as 'investors have debated the drug’s outlook' and 'fretted over whether GLP-1 weight loss drugs might reduce the need for treatments for metabolic dysfunction-associated steatohepatitis, or MASH.' However, these instances do not significantly impact the overall score as they are not directly related to logical fallacies.
]Madrigal shares surge, Wolfe says its drug is the ‘Biggest 2024 Launch in Biotech.[', 'Empirically, we have seen a doubling of diagnosis rate between 2010-2016 in MASH.']
Microsoft and Google will offer free or discounted cybersecurity services to rural hospitals in the US to protect them against cyberattacks that have disrupted patient care and threatened lives.
The Dow was having a bad Tuesday, while the S&P 500 and the Nasdaq Composite moved higher.
Apple’s shares were up 5.9% and on track for their best close yet as analysts sized up the firm’s recent artificial intelligence presentation.
Indirect bidders, such as Japan central bank and other foreign entities, took 74.6% of the debt offered to them, which is higher than their average of 63.8.
